Current Medicinal Chemistry · Nov 6, 2026

The Causal Relationship Between Cathepsin Levels and Bone Mineral Density and Osteoporosis: Evidence from Mendelian Randomization and Experimental Validation

By Shen Y, Zhu W, Fu F et al.

Introduction/Objective: While cathepsins are strongly implicated in bone remodeling and osteoporosis (OP) pathogenesis, their definitive causal relationships with bone mineral density (BMD) alterations and OP risk remain ambiguous. The specific objective of this study is to systematically investigate these interactions, hypothesizing that specific circulating cathepsins actively drive BMD alterations and OP pathogenesis. To evaluate this, we utilized a bidirectional Mendelian randomization (MR) framework, with subsequent substantiation through targeted in vivo and clinical validation. Methods: Bidirectional two-sample MR was performed using genome-wide association study (GWAS) summary statistics to assess nine circulating cathepsins against OP and BMD at various skeletal sites. Inverse variance weighting (IVW) served as the primary estimator, supplemented by comprehensive sensitivity analyses. Multivariable MR (MVMR) evaluated the joint effects of the cathepsin family, while two-step mediation MR explored immune cell phenotypes as potential mediators. Genetic associations were subsequently validated via RT-qPCR in ovariectomized (OVX) mice and ELISA in clinical serum samples. Results: Forward MR indicated that elevated Cathepsin F increases OP risk (OR = 1.00, P = 0.027) and is inversely correlated with forearm (FA) (OR = 0.94, P = 0.027) and femoral neck (FN) BMD (OR = 0.97, P = 0.017). Cathepsin L2 demonstrated a negative causal effect on FN BMD (OR = 0.96, P = 0.040), whereas Cathepsin O was positively associated with FA BMD (OR = 1.09, P = 0.037). Reverse MR suggested that lumbar spine (LS) BMD positively influences Cathepsin L2 (OR = 1.15, P = 0.033), while FA BMD inversely affects Cathepsin F (OR = 0.84, P = 0.021) and Cathepsin B (OR = 0.85, P = 0.025). Notably, MVMR adjustments for co-existing cathepsins attenuated the independent significance of these individual effects (P > 0.05). Mediation analysis revealed that the absolute count of CD11c+ monocytes mediates 17.38% of the effect of Cathepsin F on FN BMD. Experimentally, RT-qPCR and clinical ELISA consistently corroborated the significant up-regulation of Cathepsins F and L2/L, and down-regulation of Cathepsin O, in both OVX mice and patients with OP (P < 0.01). Discussion: The findings suggest that the causal effects of cathepsins on OP and BMD operate within an interconnected family network rather than in strict isolation, as revealed by MVMR. Furthermore, the partial mediation by CD11c+ monocytes highlights a complex systemic interaction involving the immune system. These results provide novel mechanistic insights into OP pathogenesis, interpreting cathepsin fluctuations not merely as consequences of bone loss, but as active contributors to the disease process. Conclusion: Cathepsins F, L2, and O exhibit robust causal associations with OP and site-specific BMD alterations. These proteins emerge as compelling candidate biomarkers for osteoporosis, offering translational potential that warrants further clinical investigation.

doi.org/10.2174/0109298673506062261025101447PubMed 43023313Mechanisms

AgingResearch.News